日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development and multinational validation of a multiple myeloma-specific comorbidity index using real-world cohorts: CAREMM-2108

利用真实世界队列开发和多国验证多发性骨髓瘤特异性合并症指数:CAREMM-2108

Choi, Suein; Byun, Ja Min; Oh, Si Eun; Han, Jinseon; Jung, Seungpil; Han, Seunghoon; Shin, Seung-Hwan; Yahng, Seung-Ah; Jeon, Young-Woo; Li, Jian; Park, Sung-Soo; Suzuki, Kazuhito; Min, Chang-Ki

Infections after bispecific antibodies in B-cell lymphomas

B细胞淋巴瘤中双特异性抗体后的感染

Kim, Dong Hyun; Lee, Naryllae; Koh, Youngil; Jo, Hyeon Jae; Kang, Chang Kyung; Choe, Pyoeng Gyun; Park, Wan Beom; Lee, Chan Mi; Byun, Ja Min; Kim, Nam Joong

Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia

纵向全外显子组测序发现克隆性造血和基因组异质性可作为新诊断老年慢性淋巴细胞白血病患者治疗结果的预测因子

Jang, Ho Cheol; Song, Ga-Young; Jeong, Hyeonjin; Byun, Ja Min; Kong, Jee Hyun; Lee, Myung-Won; Lee, Won Sik; Lee, Ji Hyun; Lee, Ho Sup; Yhim, Ho-Young; Yang, Deok-Hwan

Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study

在新型药物时代,复发/难治性多发性骨髓瘤患者的二次挽救性自体造血干细胞移植:KMM2301 研究结果

Jung, Jongheon; Lee, Ji Hyun; Kim, Sung-Hyun; Lee, Jae Hoon; Yoo, Kwai Han; Do, Young Rok; Shin, Ho-Jin; Kim, Kihyun; Yoon, Sang Eun; Yoon, Dok Hyun; Cho, Hyungwoo; Kang, Hye Jin; Byun, Ja Min; Jo, Jae-Cheol; Lee, Seung-Shin; Lee, Won Sik; Lee, Je-Jung; Jung, Sung-Hoon; Lee, Myung-Won; Yi, Jun Ho; Park, Ju-Hyun; Min, Chang-Ki; Eom, Hyeon-Seok

Prognostic Landscape of TP53 Mutations in Hematologic Malignancies

TP53突变在血液系统恶性肿瘤中的预后概况

Jang, Seo Yoon; Jang, Joowon; Lee, Jee-Soo; Seong, Moon-Woo; Park, Songyi; Byun, Ja Min; Koh, Youngil; Hong, Junshik; Kim, Inho; Yoon, Sung-Soo; Shin, Dong-Yeop

Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts

TP53突变型急性髓系白血病的独特免疫表型和临床特征:CD34/CD41高表达和白细胞计数低

Park, Songyi; Kim, Sang-A; Kim, Sheehyun; Kim, Seon Young; Lee, Ji Yun; Byun, Ja Min; Hwang, Sang Mee; Lee, Jeong-Ok; Koh, Youngil; Hong, Junshik; Chang, Yoon Hwan; Kim, Hyun Kyung; Bang, Soo-Mee; Kim, Inho; Yoon, Sung-Soo; Shin, Dong-Yeop

Real-world outcomes of inotuzumab ozogamicin treatment for adult relapsed or refractory acute lymphoblastic leukemia: a result from Korea post-marketing surveillance

inotuzumab ozogamicin治疗成人复发或难治性急性淋巴细胞白血病的真实世界疗效:来自韩国上市后监测的结果

Yoon, Jae-Ho; Lee, Jung-Hee; Yang, Deok-Hwan; Cheong, June-Won; Byun, Ja Min; Yoo, Kwai Han; Woo, Juwon; Kim, Young-Mee; Lee, Seok

Alternative splicing patterns in genetic subtypes of diffuse large B-cell lymphoma

弥漫性大B细胞淋巴瘤基因亚型中的可变剪接模式

An, Sanyeowool; Hong, Junshik; Shin, Dong-Yeop; Byun, Ja Min; Koh, Youngil; Yoon, Sung-Soo

Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study

阿扎胞苷序贯R-GDP方案治疗不适合移植的复发/难治性弥漫性大B细胞淋巴瘤:一项多中心II期研究的初步结果

Kim, Dong Hyun; Kong, Jee Hyun; Hong, Junshik; Byun, Ja Min; Shin, Dong-Yeop; Koh, Youngil; Kim, Inho; Park, Jinny; Do, Young Rok; Kim, Jeong-A; Kim, Won Seog; Shin, Ho-Jin; Yoon, Sung-Soo

Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea

韩国使用tisagenlecleucel治疗复发或难治性弥漫性大B细胞淋巴瘤的真实世界经验

Kim, Dong Hyun; Kwon, Soyean; Cha, Seungah; Öz, Rabia Seyma; Hong, Junshik; Shin, Dong-Yeop; Koh, Youngil; Yoon, Sung-Soo; Byun, Ja Min